Celecoxib clinical profile
نویسندگان
چکیده
منابع مشابه
Celecoxib clinical profile.
Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis. For both OA and RA, celecoxib has been shown to be significantly superior in efficacy to placebo and similar in efficacy to traditional non-steroidal anti-inflammatory drugs. Its advantage,...
متن کاملStylalgia Revisited: Clinical Profile and Management
Introduction: Eagle’s syndrome is a constellation of signs secondary to an elongated styloid process or due to mineralization of the stylohyoid or stylomandibular ligament or the posterior belly of the digastric muscle. The syndrome includes symptoms ranging from stylalgia (i.e. pain in the tonsillar fossa, pharyngeal or hyoid region) to foreign-body sensation in the throat, cervicofacial pain,...
متن کاملClinical profile of ARDS.
OBJECTIVES Several studies have been published in western literature on incidence, prevalence, clinical course, outcome and mortality in patients with acute respiratory distress syndrome (ARDS). There are very few studies on the pattern of ARDS seen in Indian population. There are anecdotal reports of ARDS associated with different tropical diseases and the exact association of these life-threa...
متن کاملComparison of Clinical Profile and Career Profile of Job Seekers and Waiting for Job Centers
The challenges of modern life and human nature encourage the need to earn a living and move toward materialism, in which direction jobs are the most important means of achieving this. Therefore, the purpose of the present study was to compare the clinical profile (aggression, anxiety, obsession, individual sensitivity, somatic complaints, psychosis, paranoid imagery, depression, and fear) and t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2000
ISSN: 1462-0332,1462-0324
DOI: 10.1093/rheumatology/39.suppl_2.21